Combined loss of HLA I and HLA II expression is more common in the non-GCB type of diffuse large B cell lymphoma Sir: As an immune escape mechanism, tumour cells may down-regulate expression of human leucocyte antigens (HLA). Loss of HLA classes I and II has been described in various subtypes of diffuse large B cell lymphoma (DLBCL), including the not otherwise specified (NOS) subgroup. 1, 2 We analysed HLA classes I and II expression in DLBCL-NOS to investigate whether there is an association between HLA expression, cell of origin (COO) and the recently reported FoxP1 expression in non-GCB DLBCL. 3 Seventy-seven cases of DLBCL-NOS with an almost exclusively nodal presentation were classified for COO by immunohistochemistry (IHC) according to the Hans algorithm as germinal centre B (GCB) cell-type (n = 42) or non-GCB-type (n = 35) ( Table 1) . Clinical data available from 67 cases indicated a histologically confirmed pre-existent or concurrent indolent lymphoma in 16 patients, i.e. 13 follicular lymphoma, two marginal zone lymphoma and one chronic lymphocytic leukaemia. Expression of HLA and FoxP1 was assessed by IHC; methods are described in the Supporting Information.
Significant differences (P < 0.01) in HLA loss were observed between the COO categories in the total group: loss of HLA class I in 51% of non-GCB versus 21% of GCB, of HLA class II in 37% of non-GCB versus 10% of GCB and combined loss in 34% of non-GCB versus 5% of GCB ( Figure 1A ).
In the total group, 35% of the cases showed loss of HLA class I expression, 22% showed loss of HLA class II and 18% showed loss of both, whereas 25% retained expression of both HLA classes I and II. Two lymphomas with partial loss of HLA class I and two other lymphomas with partial loss of HLA class II were considered HLA-negative.
In 51 de-novo cases loss of HLA class I was observed in 21 (41%) and loss of HLA class II in 16 (31%) cases. In 16 transformed cases, expression of HLA class I was lost in 5 (31%; Figure S2 ), two cases of which showed additional loss of class II (13%). As transformation from follicular lymphoma is associated with the GCB-type, we studied GCB-type DLBCL separately, and found loss of HLA class I in five of 14 transformed cases (36%) versus four of 28 de-novo GCB cases (14%) (P = 0.13). In consequence, the differences for HLA class I between the COO subtypes were even more pronounced after exclusion of transformed cases: 55% of non-GCB versus 14% of GCB cases showed loss of expression (P ≤ 0.01). Thus, these results were not influenced by the inclusion of 16 cases with a history of follicular lymphoma or other types of indolent lymphoma which, in line with the literature, were almost exclusively of GCBtype. Brown et al. suggested that FoxP1, a protein associated with non-GCB-type DLBCL, is related inversely with HLA class II expression. 4 A high expression of FoxP1 with a low expression of HLA class II expression was observed in normal pre-plasma cells and non-GCB-type DLBCL maturing to plasmablasts. 5 This is in line with data from the group of Rimsza et al., suggesting that loss of HLA class II is seen in DLBCL cases maturing into plasmablastic lymphoma. 2, 6 We studied the correlation between FoxP1 expression and HLA class II expression in 61 DLBCL cases (Figures S1 and S3 ). FoxP1 expression was not associated significantly with non-GCB-type DLBCL ( Table 1 ; P = 0.08). We did not find an association between FoxP1 and HLA class II expression: loss of HLA class II was associated very weakly with FoxP1 expression in both non-GCB-and GCB-type DLBCL. However, the majority of cases retained HLA class II expression while expressing high FoxP1 levels in both categories and vice versa; not all cases with low HLA class II showed high FoxP1 expression ( Figure 1B,C) . Of note, high expression of FoxP1 and HLA class II expression were excluded from analysis in the original study. 4 Furthermore, while most FoxP1-positive cases showed homogeneous staining of the tumour cells and only a few cases showed partial loss of HLA class II expression, a qualitative (intensity of staining) analysis of both proteins is not accomplished easily by immunohistochemistry.
In conclusion, we show that loss of HLA class I and/or HLA class II, in particular the double-negative signature, is much more common in non-GCB-type DLBCL than in GCB-type DLBCL. Our data support previous reports, focusing on class II expression. 6 The preferential loss of HLA class II expression in non-GCB-type DLBCL cannot be explained by a higher expression of FoxP1 alone. Correspondence 887
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Additional Supporting Information may be found in the online version of this article: Data S1. Methods. Figure S1 . Percentage of FOXP1 positive cells. A cut-off of ≥80% was used as in the literature, 4 since most cases were below 20% or 80% and higher. Figure S2 . HLA class I expression in a single case with DLBCL and co-existent follicular lymphoma (FL). The DLBCL shows loss of expression while the FL shows retained expression. Figure S3 . FoxP1 expression.
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